Harbor Health Care ETF (MEDI)
- Previous Close
24.76 - Open
24.60 - Bid 24.65 x 2200
- Ask 24.72 x 1100
- Day's Range
24.60 - 24.60 - 52 Week Range
21.86 - 28.40 - Volume
984 - Avg. Volume
2,745 - Net Assets 15.68M
- NAV 24.68
- PE Ratio (TTM) 37.52
- Yield 0.51%
- YTD Daily Total Return -0.21%
- Beta (5Y Monthly) 0.00
- Expense Ratio (net) 0.80%
The fund invests primarily in equity securities, principally common and preferred stocks of companies of any market capitalization. Under normal market conditions, the fund invests at least 80% of its net assets, plus borrowings for investment purposes, in securities of companies principally engaged in the research, development, production, or distribution of products and services related to the health care industry (“health care companies”). It is non-diversified.
Harbor
Fund Family
Health
Fund Category
15.68M
Net Assets
2022-11-16
Inception Date
Performance Overview: MEDI
View MoreTrailing returns as of 5/6/2025. Category is Health.
People Also Watch
Holdings: MEDI
View MoreTop 10 Holdings (67.44% of Total Assets)
Sector Weightings
Related ETF News
View More
Research Reports: MEDI
View MoreAmgen Earnings: On Track to Meet 2025 Guidance Following Broad-Based Growth in First Quarter
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
RatingPrice TargetAmgen Earnings: On Track to Meet 2025 Guidance Following Broad-Based Growth in First Quarter
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
RatingPrice TargetWhat does Argus have to say about MYGN?
MYRIAD GENETICS INC has an Investment Rating of HOLD; a target price of $8.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetRaising target price to $112.00
LIGAND PHARMACEUTICALS has an Investment Rating of HOLD; a target price of $112.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice Target